Are Chinese Patents Closing in on Czech Industry? The Data Tells a Different Story

• 

• 

• 

Over the past twenty years, the number of Chinese foreign patent families has grown fifteenfold: from just under 2,300 to nearly 35,000 patent families a year. On its own, that number sounds like a warning of broad technological expansion. But when we looked closely at the data - as part of an analysis we produced for the Technology Agency of the Czech Republic (TA ČR) covering 2004–2024 - a far more specific and useful picture emerged. Chinese companies protect roughly 150 patents in Czechia every year. The question we set out to answer wasn't “how many,” but “where exactly” and “what does it actually mean for individual Czech companies.”

MIC2025 wasn't the starting gun

The first surprise is timing. The main wave of Chinese patent expansion arrived before 2015, when the “Made in China 2025” (MIC2025) industrial strategy was launched. Annual growth of Chinese foreign patents actually slowed after 2015 — from a 20.8% CAGR in 2004–2014 to 2.5% afterward, albeit on a base ten times larger. So MIC2025 didn't function as a trigger, but rather as a steering framework that redirected already-underway expansion into priority technology areas: semiconductors, chemical processes, and measurement and testing.

The Czech portfolio doesn't mirror the global trend, it mirrors the Czech economy

The second finding is, in practical terms, the most important one for Czech companies. The structure of Chinese patents validated in Czechia doesn't match China's global patent portfolio (which is dominated by ICT and electronics), it surprisingly closely tracks the structure of Czech industry itself: organic chemistry (13.2%), healthcare technologies (9%), and machine parts and lighting are all above average. China isn't protecting commodity patents in Czechia at random, it's targeting fields where Czech players already matter.

Within the V4 region, Czechia isn't the main regional target either. Hungary and Slovakia are far more exposed per capita, and Czech exposure is comparable to Poland's. Austria's exposure to Chinese patent activity exceeds Czechia's by 60–90x per capita.

The real risk isn't at home but in export markets

This is where we arrive at the finding that, in our view, changes the whole framing of the “Chinese threat” debate. Czechia isn't the primary target of Chinese patent protection across most key MIC2025 domains, but Czech companies export heavily. And it's precisely in the markets where that export goes that Chinese patent expansion is fastest. China's share of the global patent portfolio grew between 2004 and 2024 by 459% in semiconductors, 312% in control and regulation, 215% in chemical processes, 213% in measurement and testing, and 182% in biotechnology.

In other words: a company that only tracks how many patents China protects directly in Czechia may have a false sense of security. The competitive pressure is playing out elsewhere — in the markets where that company actually sells.

It's not about volume, it's about strategically valuable niches

When we looked at the value of individual patents rather than their count, the picture sharpened further. The highest-valued patents in China's Czech portfolio aren't in the most numerous classes, but in narrowly defined niches: a computing patent is worth an average of $8.6 million, a biotechnology patent $7.8 million, a communications patent $7.4 million. Chinese companies aren't competing on portfolio volume, they're defending specific market positions where it counts.

The asymmetry can be sharp by sector. In telecommunications, within our sample of 27 Czech companies, we counted 199 Chinese patents against 6 Czech ones — a 33:1 ratio. By contrast, in healthcare technologies, measurement and testing, and textile fibers, Czech companies hold a comparable or stronger position.

No proven direct hit to revenue but indirect risk can't be ruled out

Statistical analysis of a sample of 27 innovative Czech companies and research organizations found no direct link between Chinese patent exposure and revenue growth (p = 0.882). That's good news, but it should be read carefully. Detailed case studies across four sectors (automotive, biotechnology, software, and 3D printing) show that pressure from China operates indirectly, and differently in each sector. In automotive, it's mainly price competition and component copying; in biotechnology, a rapidly growing number of potentially conflicting patents; in software, so far more about regulatory and data risk than direct patent disputes; in 3D printing, a combination of low prices and fast-adapting competitors.

What this means for companies

The data points to a recommendation that runs against the intuitive “keep an eye on patents at home”: companies should stop monitoring Chinese patent activity broadly and instead focus where the asymmetry is sharpest and where they actually sell - which often means looking beyond Czech jurisdiction. There's also no one-size-fits-all IP strategy, according to the case studies. Automotive manufacturers rely on speed of development and know-how protection; biotech companies need to budget for costly patent enforcement; software companies protect source code and their partner ecosystem above all. A patent alone doesn't guarantee protection - it's just one tool within a broader IP strategy.

“Chinese patent activity in Czechia doesn't directly threaten most companies but if they're only watching the domestic market, they're watching the wrong place. What matters is what's happening in the markets we actually export to: in semiconductors or in control and regulation, Chinese companies are expanding several times faster there than at home. A patent alone won't protect a company either - you can see that in the difference between automotive, where speed of development and know-how protection matter most, and biotechnology, where the ability to actually enforce a patent is what counts,”

says Vojtech Kadlec, Co-CEO, UNICO Analytics.

The bottom line

Twenty years of data confirm neither the picture of a blanket “Chinese patent encirclement” nor the opposite conclusion that this is just harmless market competition. The reality is more specific and more useful for companies: Chinese patent activity in Czechia mirrors the structure of domestic industry, but the biggest risk lies abroad, in the export markets Czech companies sell into, concentrated in a handful of precisely targeted, high-value niches. Companies that understand this distinction can better target their own IP strategy and know where and how to actually watch the competition.

The full analysis, “China's Patent Strategy 2004–2024 and Its Impact on the Czech Innovation Ecosystem,” produced by UNICO Analytics for TA ČR, is available here: https://tacr.gov.cz/wp-content/uploads/2026/08/Patentova-Strategie-Ciny-.pdf (in Czech).

The analysis draws on data from PatSnap, MagnusWeb, and the Czech Statistical Office (ČSÚ) for 2004–2024, with the patent family (IPC/WIPO) as the base unit. The company comparison uses a sample of 27 selected innovative businesses and research organizations (top grant recipients, DELTA program participants, INKA mapping).